A
Anna Maria Langkilde
Researcher at AstraZeneca
Publications - 182
Citations - 11140
Anna Maria Langkilde is an academic researcher from AstraZeneca. The author has contributed to research in topics: Dapagliflozin & Medicine. The author has an hindex of 37, co-authored 107 publications receiving 5784 citations. Previous affiliations of Anna Maria Langkilde include University of Groningen & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink,Bergur V. Stefánsson,Ricardo Correa-Rotter,Glenn M. Chertow,Thomas F. Greene,Fan Fan Hou,Johannes F.E. Mann,John J. V. McMurray,Magnus Lindberg,Peter Rossing,C. David Sjöström,R D Toto,Anna Maria Langkilde,David C. Wheeler +13 more
TL;DR: Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo.
Journal ArticleDOI
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
Jan Bolinder,Östen Ljunggren,Joel Kullberg,Lars Johansson,Lars Johansson,John P.H. Wilding,Anna Maria Langkilde,Jennifer Sugg,Shamik Parikh +8 more
TL;DR: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin and establishes through body composition measurements whether weight loss is accounted for by changes in fat or fluid components.
Journal ArticleDOI
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Jan Bolinder,Östen Ljunggren,Lars Johansson,Lars Johansson,John P.H. Wilding,Anna Maria Langkilde,C. D. Sjöström,Jennifer Sugg,Shamik Parikh +8 more
TL;DR: Dapagliflozin reduces hyperglycaemia and weight in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion and long‐term glycaemic control, body composition and bone safety were evaluated.
Journal ArticleDOI
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon,Stephen D. Wiviott,Avivit Cahn,Aliza Rozenberg,Ilan Yanuv,Erica L. Goodrich,Sabina A. Murphy,Hiddo J.L. Heerspink,Thomas A Zelniker,Jamie P. Dwyer,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Eri Toda Kato,Ingrid Gause-Nilsson,Martin Fredriksson,Peter A. Johansson,Anna Maria Langkilde,Marc S. Sabatine,Itamar Raz +20 more
TL;DR: Both the cardiorenal and renal-specific composite outcomes were improved with dapagliflozin versus placebo across various prespecified subgroups, including those defined by baseline eGFR.
Journal ArticleDOI
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri Toda Kato,Michael G. Silverman,Ofri Mosenzon,Thomas A Zelniker,Avivit Cahn,Remo H.M. Furtado,Julia F Kuder,Sabina A. Murphy,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc P. Bonaca,Christian T. Ruff,Akshay S. Desai,Shinya Goto,Peter A. Johansson,Ingrid Gause-Nilsson,Per Johanson,Anna Maria Langkilde,Itamar Raz,Marc S. Sabatine,Stephen D. Wiviott +22 more
TL;DR: In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, it is found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in Patients with HFr EF.